Wed. 13 Mar 2024, 8:15am ET
Benzinga
Earnings, News
Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.26) by 30.77 percent. This is a 6.25 percent decrease over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $2.04 million which missed the analyst consensus estimate of $8.10 million by 74.79 percent. This is a 92.50 percent decrease over sales of $27.23 million the same period last year.